The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, Robin L, Goodwin, Guy M·2017·Neuropsychopharmacology
DOI 10.1038/npp.2017.84

Cited by (702)

Items 301–400 of 702

  1. Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential
    Priyanshu Raj, Shyambabu P. Rauniyar, Bhagyesh Sapkale · 2023 · Cureus
  2. The computational unconscious: Adaptive narrative control, psychopathology, and subjective well-being
    George Deane, Jonas Mago, Aikaterini Fotopoulou, Matthew D. Sacchet, Robin Lester Carhart-Harris, Lars Sandved-Smith · 2024
  3. Comprehensive Analysis of 42 Psilocybin-Producing Fungal Strains Reveals Metabolite Diversity and Species-Specific Clusters
    Cohen, Jonathan, Sulimani, Liron, Procaccia, Shiri, Lerenthal, Yaniv, Milay, Looz, Taran, Ido, Shapira, Anna, Meiri, David · 2025 · Scientific Reports
  4. Psychedelics in Psychiatry, the Nursing Influence, and the Future of Psychedelic Therapies
    Carlton J. Spotswood · 2024 · Journal of the American Psychiatric Nurses Association
  5. The historical opposition to psychedelic research and implications for credibility in psychiatry
    Elena Koning, Elvina May-Yin Chu, Elisa Macedo Brietzke · 2024 · CNS Spectrums
  6. Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies
    William Roseby, Hannes Kettner, Leor Roseman, Meg J. Spriggs, Taylor Lyons, Joe Peill, Bruna Giribaldi, David Erritzøe, David John Nutt, Robin Lester Carhart-Harris · 2025 · Frontiers in Psychology
  7. The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
    Dongsun Park, Gwangho Lee, Won-Gyu Lee, B.S. Kim, Yoonji Lee, Ji‐Woon Kim · 2025 · Molecular Psychiatry
  8. Biased Signaling in Psychedelic Action
    Daniel Wacker, John D. McCorvy · 2025 · The Annual Review of Pharmacology and Toxicology
  9. Exploring the therapeutic potential of psychedelics in treating substance use disorders
    Y Li, Hongyuan Li, Hongshuang Wang, Xiaohui Wang · 2025 · Molecular Psychiatry
  10. A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
    Jaden Brandt · 2023 · Drug Science Policy and Law
  11. Lifetime classic psychedelic use is associated with greater psychological distress in unemployed job seekers
    Benjamin A. Korman · 2023 · Journal of Psychedelic Studies
  12. How to tell the mushroom you are holding will kill you or heal you: A mini review
    Ashutosh Singh Sisodiya, Ardra Sajan Kadicheeni, Gaurab Das, Tejaswini Kumari, T. S. Archana, Devendra Kumar · 2023 · The Pharma Innovation
  13. Psychedelic-assisted therapy for people with gambling disorder?
    Pedro Romero, Andrea Czakó, Wim van den Brink, Zsolt Demetrovics · 2024 · Journal of Behavioral Addictions
  14. Ayahuasca for the treatment of alcohol use disorder
    E.A.V. Marinho, Yasmim A. Serra, Alexandre J. Oliveira-Lima, Tânia Marcourakis, Lais Fernanda Berro · 2024 · International review of neurobiology
  15. Unraveling the metabolomic profile and acute toxicity of ethanolic extract from Mimosa tenuiflora (Willd.) Poir. root bark
    Renato Pinto de Sousa, Carlos Mário Freitas de Oliveira, Rita de Cassia de Lima Sousa, Lucas Luan Lima Leite, André Luiz Ozório Oliveira, Jady Vitória Barjud Pereira Ferreira, Ana Márcia de Freitas Pessoa, Jorge Luiz Silva Oliveira, Victor de Jesus Silva Meireles, Esmeralda Maria Lustosa Barros et al. · 2024 · Toxicon
  16. A new ethos for science? Exploring emerging DIY science “qualities”
    Federico Ferretti, Ângela Guimarães Pereira · 2020 · Futures
  17. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta‐analysis of randomised controlled trials in healthy volunteers
    Hang Li, Yi Zhong, Siyuan Yang, Jiahe Wang, Xiang Li, Jianguo Xu, Heng Gao, Gang Chen · 2021 · Human Psychopharmacology Clinical and Experimental
  18. Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism
    Benjamin A. Korman · 2023 · Journal of Psychedelic Studies
  19. Global species diversity and distribution of the psychedelic fungal genus Panaeolus
    Dominique Strauss, Soumya Bikash Ghosh, Zurika Murray, Marieka Gryzenhout · 2023 · Heliyon
  20. Psychedelic treatments are speeding towards approval — but no one knows how they work
    Sara Reardon · 2023 · Nature
  21. Can research on entactogens contribute to a deeper understanding of human sexuality?
    Justyna Holka-Pokorska · 2023 · Pharmacological Reports
  22. The Promise and Demise of LSD Psychotherapy in Norway
    Per Haave, Willy Pedersen · 2019 · Social History of Medicine
  23. 5-MeO-DALT: the freebase of N,N-diallyl-5-methoxytryptamine
    A.R. Chadeayne, Duyen N. K. Pham, James A. Golen, David R. Manke · 2020 · IUCrData
  24. Crystal structure of serotonin
    Marilyn Naeem, A.R. Chadeayne, James A. Golen, David R. Manke · 2022 · Acta Crystallographica Section E Crystallographic Communications
  25. Psychedelic Mysticism and Christian Spirituality: From Science to Love
    Ron Cole‐Turner · 2024 · Religions
  26. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review
    Laura Ramos, Selene Vicente · 2024 · Journal of Clinical and Experimental Neuropsychology
  27. A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies
    Olga Wachełko, Karolina Nowak, Kaja Tusiewicz, Marcin Zawadzki, Paweł Szpot · 2024 · The Analyst
  28. Psychedelic use and bipolar disorder – An investigation of recreational use and its impact on mental health
    Thomas Daniel Meyer, Maya Ibrahim, L. Vale, Jair C. Soares · 2024 · Journal of Affective Disorders
  29. Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings
    Megan Calnan, Grace Blest‐Hopley, Chris Busch, Milly Adams, Simon Ruffell, Theodore Piper, Leor Roseman, Hannes Kettner, Robin Lester Carhart-Harris · 2025 · Brain and Behavior
  30. Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin
    Ross J. Purple, Rahul Gupta, Christopher W. Thomas, Caroline T. Golden, Nicola Palomero‐Gallagher, Robin Lester Carhart-Harris, Seán Froudist‐Walsh, Matthew W. Jones · 2025 · Molecular Psychiatry
  31. The Key Role of Intracellular 5-HT2A Receptors: A Turning Point in Psychedelic Research?
    Jacopo Sapienza · 2023 · Psychoactives
  32. “He’s used drugs - he’s biased! He’s not a drug user - what would he know!”: A cross-sectional, online study of drug researchers’ experiential knowledge of drug use and disclosure
    Danielle C. Ompad, Cho‐Hee Shrader, Kyle M. Snyder, Jules Netherland, Sheila P. Vakharia, Ingrid Walker · 2024 · Drug and Alcohol Dependence Reports
  33. The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication
    Elena Koning, Marco Solmi, Elisa Macedo Brietzke · 2024 · Trends in Psychiatry and Psychotherapy
  34. The hydrochloride salt of 4-hydroxy-N,N-di-n-propyltryptamine (4-HO-DPT)
    Vamshikrishna Reddy Sammeta, Sivappa Rasapalli, A.R. Chadeayne, James A. Golen, David R. Manke · 2020 · IUCrData
  35. Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
    Annie McCartney, Hugh T. McGovern, Alexander De Foe · 2022 · Journal of Psychedelic Studies
  36. Biological studies of clavine alkaloids targeting CNS receptors
    Nikhil R. Tasker, Ethan J. Pazur, Peter Wipf · 2023 · Frontiers in Psychiatry
  37. Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists
    Navoda Jayakodiarachchi, Mallory A. Maurer, Daniel Schultz, Cayden J. Dodd, Analisa Thompson Gray, Hyekyung P. Cho, Olivier G. Boutaud, Carrie K. Jones, Craig W. Lindsley, Aaron M. Bender · 2024 · ACS Medicinal Chemistry Letters
  38. Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences
    Joseph T. La Torre, Jade Gallo, Mehdi Mahammadli, Daniel Zalewa, Monnica T. Williams · 2024 · Journal of Psychedelic Studies
  39. Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy
    Courtney Campbell Walton, Paul Liknaitzky · 2020 · Journal of Applied Sport Psychology
  40. Imagining a Role for Psychedelics in Dementia Care
    Daniel R. George, Ryan Hanson · 2019 · American Journal of Geriatric Psychiatry
  41. Racial Differences in Naturalistic Psychedelic Use — Motivations for Use, Communication with Health Care Providers, and Outcomes
    Nicolas G. Glynos, Mallet R. Reid, Jacob S. Aday, Daniel J. Kruger, Kevin F. Boehnke, Stephanie Lake, Philippe Lucas · 2025 · Journal of Psychoactive Drugs
  42. The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews
    Sabrina Corrêa da Costa, Nicholas L. Bormann, Tyler Oesterle, Michele T. McGinnis, Ming‐Fen Ho, Sara A. Vettleson-Trutza, Teresa A. Rummans, Mark S. Gold · 2025 · Brain Sciences
  43. Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes
    Giacomo d’Andrea, Stefania Chiappini, Laura Ciavoni, Rolando Tucci, Fabrizio Martino, Francesco Maria Semeraro, Daniele Di Battista, Alessio Mosca, Andrea Miuli, Francesco Di Carlo et al. · 2025 · Translational Psychiatry
  44. Psychedelic Drug Microdosing Practices: A Qualitative Online Exploration
    Estelle Miller, Vida Bojovic, Olivia Maddren, Prashant Rao, Dami Adesina, Anastasia Petrenko, Rhys Ponton · 2024 · Journal of Psychoactive Drugs
  45. Aggressive behaviours associated with MDMA and psychedelics: a narrative review
    Negar Sayrafizadeh, Nicole Ledwos, Muhammad Ishrat Husain, David Jonathan Castle · 2024 · Acta Neuropsychiatrica
  46. Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study
    Jacob S. Aday, Emily K. Bloesch, Alan K. Davis, Sarah E. Domoff, Kyle Christopher Scherr, Josh D. Woolley, Christopher C. Davoli · 2024 · Journal of Humanistic Psychology
  47. The psychedelic mind: Current user perceptions of psychedelic drugs and their use
    Sarah McGruddy, Jai Whelan, Ethan Mills, Alexander Boardman, Ryan D. Ward · 2024 · Drugs, Habits and Social Policy
  48. Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials
    Patrick Köck, Andrzej Badek, Maximilian Meyer, Arndt-Lukas Klaassen, Marc Walter, Jochen Kindler · 2024 · Child and Adolescent Psychiatry and Mental Health
  49. The Rising Use of LSD among Business Managers
    Benjamin A. Korman · 2023 · Substance Use & Misuse
  50. ‘Psychedelics are no magic pill’: the narrative and embodied dimensions of psychedelic integration in Denmark
    Sidsel Marie · 2024 · Anthropology of Consciousness
  51. Photoswitchable TCB-2 for control of the 5-HT 2A receptor and analysis of biased agonism
    Alireza Jafar Esmaeili, Pantea Montazeri, Jasmine Cristina Gomez, Didier J. Dumervil, Faezeh Safar Nezhad, Rachel C. Steinhardt · 2024 · Chemical Communications
  52. Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology
    Matthew Moroz, Robin Lester Carhart-Harris · 2018
  53. Antidepressants
    Richard A. Glennon, Leslie Lars Iversen · 2021 · Wiley eBooks
  54. Sleep-like state during wakefulness induced by psychedelic 5-MeO-DMT in mice
    Benjamin J. B. Bréant, José Prius-Mengual, Anna Hoerder-Suabedissen, Jasmin Patel, David M. Bannerman, Trevor Sharp, Vladyslav V. Vyazovskiy · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  55. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
    Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi, Sandra Horschitz, Thorsten Lau, Marcus W. Meinhardt, Rainer Spanagel, Julia Ladewig, Georg Köhr, Philipp Koch · 2024 · Research Square
  56. Psychedelics and the Autonomic Nervous System: A Perspective on Their Interplay and Therapeutic Potential
    Hongyuan Li, Hongshuang Wang, Xiaohui Wang · 2025 · ACS Pharmacology & Translational Science
  57. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
    Malin Schmidt, Anne Hoffrichter, Mahnaz Davoudi, Sandra Horschitz, Thorsten Lau, Marcus W. Meinhardt, Rainer Spanagel, Julia Ladewig, Georg Köhr, Philipp Koch · 2025 · eLife
  58. Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review
    Jaime Moreno‐Chaparro, Gabriela Castañeda-Millán, Javier Hernando Eslava-Schmalbach · 2025 · Clinical Neuropharmacology
  59. Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia
    Jacopo Sapienza, Marco Spangaro, Stefano Comai, Michel Sabé, Joseph T. La Torre, Matteo Buonarroti, Roberto Cavallaro, Marta Bosia · 2025 · International Journal of Molecular Sciences
  60. Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review
    Stanley Wong, Brett D. M. Jones, Mathura T. Thiyagarajah, Sami George Sabbah, Chase W. Thompson, Marco Solmi, Madeha Umer, Christoph Zrenner, Daphne Voineskos, Joshua Daniel Rosenblat et al. · 2025 · Therapeutic Advances in Psychopharmacology
  61. Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
    Charalampos L. Kandilakis, Costas Papatheodoropoulos · 2026 · ACS Chemical Neuroscience
  62. Microglial phagocytosis and regulatory mechanisms: Key players in the pathophysiology of depression
    Man Wang, Guimin Jin, Tingting Duan, Run Li, Yubin Gao, Ming Yu, Yuhao Xu · 2025 · Neuropharmacology
  63. Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease
    Stephan C. Tap, Tijmen Bostoen, Joost J. Breeksema, Robert A. Schoevers · 2025 · International review of neurobiology
  64. Feasibility of a Hypnosis Intervention for a Mystical Experience
    Chris Corlett, Cameron T. Alldredge, Gary R. Elkins · 2025 · International Journal of Clinical and Experimental Hypnosis
  65. LSD: Mechanisms and relevance to the treatment of depression
    Amel Bouloufa, Sarah Delcourte, Thomas Delannay, Renaud Rovera, Thorsten Lau, Lionel Moulédous, Ouria Dkhissi‐Benyahya, Bruno Pierre Guiard, Nasser Haddjeri · 2025 · Neuroscience & Biobehavioral Reviews
  66. Synthesis and structure of 4-hydroxy- N -isopropyltryptamine (4-HO-NiPT) and its precursors
    Uroš Laban, Marilyn Naeem, A.R. Chadeayne, James A. Golen, David R. Manke · 2023 · Acta Crystallographica Section E Crystallographic Communications
  67. LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain
    J Van Der Walt, Romy Parker · 2023 · South African Medical Journal
  68. Chronic Behavioral and Neurochemical Effects of Four Novel N-Benzyl-2-phenylethylamine Derivatives Recently Identified as “Psychoactive” in Adult Zebrafish Screens
    Nikita P. Ilyin, Arslan D. Nabiullin, Anna D. Kozlova, Olga V. Kupriyanova, Vadim A. Shevyrin, Tatyana A. Gloriozova, Dmitry A. Filimonov, Alexey A. Lagunin, David S. Galstyan, Tatiana O. Kolesnikova et al. · 2024 · ACS Chemical Neuroscience
  69. Perspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
    Sean P. Kinahan, Elizabeth Jane Wilson · 2025 · Counselling and Psychotherapy Research
  70. Comparing psychedelic and meditation experience reports with natural language processing
    Konsta Kallio-Mannila, Rosa Salmela, Jussi Jylkkä · 2025 · Scientific Reports
  71. The metaphysics behind pharmacotherapy: treating depression with conventional and psychedelic drugs
    Virginia Ballesteros · 2018 · Psicología Conocimiento y Sociedad
  72. Inducing Effects of Illegal Drugs to Improve Mental Health by Self-Regulation Therapy: A Pilot Study
    Salvador Amigó · 2021 · International Journal of Environmental Research and Public Health
  73. Studying Close Entity Encounters of the Psychedelic Kind: Insights from the Cognitive Evolutionary Science of Religion
    F. LeRon Shults · 2022 · International Journal for the Psychology of Religion
  74. A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach
    Lucas Pinheiro Coutinho, Sérgio Ruschi Bergamachi Silva, Pedro de Lima‐Neto, Norberto de Kássio Vieira Monteiro · 2023 · Biochemical and Biophysical Research Communications
  75. The Evolving Role of History in the Past, Present, and Future of Psychedelic Patenting
    Shahin Shams, Amanda Rose Pratt, Sisi Li, Tom Isenbarger · 2023 · History of Pharmacy and Pharmaceuticals
  76. Break on Through: Betty Eisner's Problematic Use of Psychedelics, Groups, and Control for Integrative Experiences
    Tal Davidson, Patric Plesa · 2025 · Journal of the History of the Behavioral Sciences
  77. Microdosing Psychedelics as a Promising New Pharmacotherapeutic
    Kim P. C. Kuypers · 2021 · Springer eBooks
  78. Personality and demographic characteristics of parents who occasionally use psychoactive substances
    Vered Ne’eman-Haviv, Yael Wilchek‐Aviad · 2022 · International Journal of Psychology
  79. Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside
    Min Cai, Huaning Wang, Xia Zhang · 2019 · Advances in experimental medicine and biology
  80. Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice
    Christopher W. Thomas, Cristina Blanco‐Duque, Benjamin J. B. Bréant, Guy M. Goodwin, Trevor Sharp, David M. Bannerman, Vladyslav V. Vyazovskiy · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  81. Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape
    Andrea I. Luppi, Justine Y. Hansen, R. Adapa, Robin Lester Carhart-Harris, Leor Roseman, Christopher Timmermann, Daniel Golkowski, Andreas Ranft, Rüdiger Ilg, Denis Jordan et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  82. LSD microdosing attenuates the impact of temporal priors in time perception
    Renata Sadibolova, Clare Murray-Lawson, Neiloufar Family, Luke T. J. Williams, David P. Luke, D. Terhune · 2023 · bioRxiv
  83. Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI
    Robert B. Kargbo · 2023 · ACS Medicinal Chemistry Letters
  84. Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex
    Rick T. Zirkel, Matthew D. Isaacson, Clara Liao, Matthew Yi, Keri Yamaguchi, Daniel Rivera, Amy F. Kuceyeski, Nozomi Nishimura, Alex C. Kwan, Chris B. Schaffer · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution
    Stanisław Adamczyk, Małgorzata Paczyńska, Anastasia Ruban, Jan Szczypiński, Michał Bola, Paweł Orlowski · 2025 · Journal of Psychoactive Drugs
  86. “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke
    Patricia A. Cioe, Garrett S Stang, Danish Azam, Sarah Dugal · 2025 · Addiction Science & Clinical Practice
  87. The potential risks of opening the mind’s eye with psychedelic therapies
    Roger Koenig‐Robert, Rebecca Keogh, Joel Pearson · 2025 · Cortex
  88. Psychedelics for substance use disorders: are women being addressed? A scoping review
    Alexandra Wojdyslawski Nigri, Ilana Falcão de Arruda, Catarina Gouveia Ferreira Maia, Luís Fernando Tófoli, Fábio Carezzato · 2025 · International Journal of Drug Policy
  89. Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
    Luisina Castelli Rodríguez, Guillermo Morera, Sandra Lupo, Danilo Davyt, Ignacio Carrera, Gonzalo Hernández Dossi · 2025 · ACS Omega
  90. Sanitizing psychedelics: the biopolitics of non-hallucinogenic psychoplastogens
    Ido Hartogsohn · 2026 · BioSocieties
  91. Fungi as Therapeutics: Bridging Traditional Wisdom and Modern Medicine
    Bidhan Mahajon, Rupashri Nath, Santosh Kumar Thakur, Manish Kumar Gautam, Sandip Mondal, Nur Shaid Mondal, Arup Dey, Partha Pratim Dutta · 2026 · New Zealand Journal of Botany
  92. How to set up a psychedelic study: Unique considerations for research involving human participants
    Marcus J. Glennon, Catherine Bird, Prateek Yadav, Patrick Kleine, Shayam Suseelan, Christina Boman-Markaki, Vasileia Kotoula, Matt Butler, Robert Leech, Leor Roseman et al. · 2026 · Neuroscience & Biobehavioral Reviews
  93. Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress
    Noah D. Gold, Samantha K. Podrebarac, Lindsay A. White, Christina Marini, Naomi M. Simon, Mary Sherman Mittelman, Stephen Ross, Michael P. Bogenschutz, Petros D. Petridis · 2023 · Psychedelic Medicine
  94. Complex emotional experiences: theoretical significance, ways of induction and therapeutic potential
    D. A. Salikova, Vladimir Kosonogov · 2025 · Current Psychology
  95. Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners
    Shannon Hughes, Lucia Terpak, Reilly Capps, Pam Peters, Nicole Lilly, Dylan Rivard · 2025 · Journal of Psychedelic Studies
  96. Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
    Clarissa G. Yates, Jennifer L. Kruse, J. Blair Price, Avril A. B. Robertson, Susannah J. Tye · 2021 · Current Treatment Options in Psychiatry
  97. A long trip into the universe: Psychedelics and space travel
    Leonard B. Lerer, Jeet Chandrakant Varia · 2022 · Frontiers in Space Technologies
  98. The methanol and ethanol solvates of 4-glutarato-N,N-diisopropyltryptamine
    Marilyn Naeem, Barbara E. Bauer, A.R. Chadeayne, James A. Golen, David R. Manke · 2022 · Acta Crystallographica Section E Crystallographic Communications
  99. Interval delivery of 5HT2A agonists using multilayered polymer films
    Mehjabeen Hossain, Suresh Ponnayyan Sulochana, Katie E. Heath, Saif Mohammad Ishraq Bari, Parker R. Brewster, Jared Barnes, Azim Munivar, Glenn M. Walker, David A. Puleo, Thomas A. Werfel · 2023 · Journal of Biomedical Materials Research Part A
  100. The use of psychedelics in psychiatric treatment – evolutionary perspectives
    Gurjot Brar, Henry P. O'Connell · 2023 · Irish Journal of Psychological Medicine